{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:30:49Z","timestamp":1794036649110,"version":"4.8.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.molmed.2016.01.001","type":"journal-article","created":{"date-parts":[[2016,1,31]],"date-time":"2016-01-31T16:30:30Z","timestamp":1454257830000},"page":"230-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":376,"title":["IL-17 in Chronic Inflammation: From Discovery to Targeting"],"prefix":"10.1016","volume":"22","author":[{"given":"Audrey","family":"Beringer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Noack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Miossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2016.01.001_bib0530","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0535","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/eji.201242605","article-title":"Immunity to infection in IL-17-deficient mice and humans","volume":"42","author":"Cypowyj","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0540","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and Th17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2016.01.001_bib0545","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0550","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0555","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.molmed.2016.01.001_bib0560","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cytogfr.2010.10.002","article-title":"IL-17 family member cytokines: regulation, and function in innate immunity","volume":"21","author":"Reynolds","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.molmed.2016.01.001_bib0565","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0570","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1084\/jem.20061738","article-title":"IL-25 regulates Th17 function in autoimmune inflammation","volume":"204","author":"Kleinschek","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0575","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/1074-7613(95)90070-5","article-title":"Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor","volume":"3","author":"Yao","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2016.01.001_bib0580","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.coi.2011.07.006","article-title":"Recent advances in the IL-17 cytokine family","volume":"23","author":"Gaffen","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0585","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/ncomms2880","article-title":"Crystal structures of interleukin 17A and its complex with IL-17 receptor A","volume":"4","author":"Liu","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2016.01.001_bib0590","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23\u2013IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0595","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4049\/jimmunol.180.1.655","article-title":"IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood","volume":"180","author":"Zrioual","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0600","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4049\/jimmunol.162.3.1246","article-title":"IL-17 is produced by some proinflammatory Th1\/Th0 cells but not by Th2 cells","volume":"162","author":"Aarvak","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0605","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","article-title":"Human IL-17: a novel cytokine derived from T cells","volume":"155","author":"Yao","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0610","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.4049\/jimmunol.165.11.6107","article-title":"Microbial lipopeptides induce the production of IL-17 in Th cells","volume":"165","author":"Infante-Duarte","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0615","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.coi.2007.07.020","article-title":"Th17: the third member of the effector T cell trilogy","volume":"19","author":"Bettelli","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0620","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2016.01.001_bib0625","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0630","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.molmed.2016.01.001_bib0635","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2016.01.001_bib0640","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: the sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0645","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2016.01.001_bib0650","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2016.01.001_bib0655","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.4049\/jimmunol.167.10.6015","article-title":"Enhancing effect of IL-1, IL-17, and TNF-\u03b1 on macrophage inflammatory protein-3\u03b1 production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines","volume":"167","author":"Chabaud","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0660","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1165\/ajrcmb.25.3.4424","article-title":"Interleukin-17 and lung host defense against Klebsiella pneumoniae infection","volume":"25","author":"Ye","year":"2001","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0665","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","article-title":"Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses","volume":"30","author":"Ishigame","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2016.01.001_bib0670","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1172\/JCI40891","article-title":"IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice","volume":"120","author":"Cho","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2016.01.001_bib0675","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.20081463","article-title":"Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis","volume":"206","author":"Conti","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0680","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.4049\/jimmunol.1001153","article-title":"IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans","volume":"185","author":"Kagami","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0685","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1084\/jem.20080321","article-title":"Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells","volume":"205","author":"de Beaucoudrey","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0690","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.molmed.2016.01.001_bib0695","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.aaa4282","article-title":"Immunodeficiencies. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations","volume":"349","author":"Okada","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.molmed.2016.01.001_bib0700","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E","article-title":"Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium","volume":"42","author":"Chabaud","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2016.01.001_bib0705","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.4049\/jimmunol.0901942","article-title":"IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2\/monocyte chemoattractant protein-1 induction","volume":"184","author":"Shahrara","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0710","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4049\/jimmunol.161.1.409","article-title":"Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines","volume":"161","author":"Chabaud","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0715","doi-asserted-by":"crossref","first-page":"e13416","DOI":"10.1371\/journal.pone.0013416","article-title":"Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression","volume":"5","author":"Toh","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2016.01.001_bib0720","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.21342","article-title":"Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis","volume":"52","author":"Koenders","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2016.01.001_bib0725","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T","article-title":"The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model","volume":"44","author":"Chabaud","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2016.01.001_bib0730","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.4049\/jimmunol.0801967","article-title":"Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes","volume":"182","author":"Zrioual","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0735","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.4049\/jimmunol.179.6.4135","article-title":"IL-17 enhances chemokine gene expression through mRNA stabilization","volume":"179","author":"Hartupee","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0740","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/art.38896","article-title":"Combined inhibition of tumor necrosis factor \u03b1 and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody","volume":"67","author":"Fischer","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0745","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2016.01.001_bib0750","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0755","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0760","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.molmed.2016.01.001_bib0765","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10067-011-1737-y","article-title":"Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA","volume":"30","author":"Metawi","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0770","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2016.01.001_bib0775","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis","volume":"30","author":"Mei","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0780","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2016.01.001_bib0785","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2016.01.001_bib0790","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","article-title":"Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis","volume":"74","author":"Ciccia","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2016.01.001_bib0795","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.21652","article-title":"T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-\u03b2","volume":"65","author":"Durelli","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0800","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","article-title":"Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis","volume":"172","author":"Tzartos","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0805","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2016.01.001_bib0810","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ni0609-568","article-title":"IL-17A directly inhibits Th1 cells and thereby suppresses development of intestinal inflammation","volume":"10","author":"Awasthi","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0815","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00011-014-0768-7","article-title":"Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease","volume":"63","author":"Jiang","year":"2014","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.molmed.2016.01.001_bib0820","doi-asserted-by":"crossref","first-page":"690853","DOI":"10.1155\/2014\/690853","article-title":"Serum interleukin 17 levels in patients with Crohn's disease: real life data","volume":"2014","author":"Sahin","year":"2014","journal-title":"Dis. Markers"},{"key":"10.1016\/j.molmed.2016.01.001_bib0825","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1097\/MIB.0b013e3182a85709","article-title":"Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients","volume":"19","author":"Ueno","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.molmed.2016.01.001_bib0830","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrd4518","article-title":"Targeting the IL-17-Th17 pathway","volume":"14","author":"Bartlett","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2016.01.001_bib0835","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/annrheumdis-2014-eular.4676","article-title":"FRI0303 discovery and characterization of Abt-122, an anti-TNF\/IL-17 DVD-Ig molecule as a potential therapeutic candidate for rheumatoid arthritis","volume":"73","author":"Hsieh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2016.01.001_bib0840","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/annrheumdis-2015-eular.4042","article-title":"FRI0156 pharmacokinetics of ABT-122, a dual TNF- and IL-17A-targeted DVD-IG\u2122, after single dosing in healthy volunteers and multiple dosing in subjects with rheumatoid arthritis","volume":"74","author":"Ahmed","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2016.01.001_bib0845","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/19420862.2015.1093266","article-title":"Discovery and characterization of COVA322, a clinical-stage bispecific TNF\/IL-17A inhibitor for the treatment of inflammatory diseases","volume":"8","author":"Silacci","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.molmed.2016.01.001_bib0850","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.drudis.2014.04.012","article-title":"Inhibiting ROR\u03b3t\/Th17 axis for autoimmune disorders","volume":"19","author":"Isono","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.molmed.2016.01.001_bib0855","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature10075","article-title":"Suppression of Th17 differentiation and autoimmunity by a synthetic ROR ligand","volume":"472","author":"Solt","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2016.01.001_bib0860","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2014.04.004","article-title":"Small-molecule ROR\u03b3t antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms","volume":"40","author":"Xiao","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2016.01.001_bib0865","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0870","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2013 results of two Phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0875","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0880","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0885","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two Phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2016.01.001_bib0890","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0895","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","article-title":"Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment","volume":"71","author":"Papp","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0900","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0905","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0910","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A Phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0915","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2016.01.001_bib0920","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a Phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0925","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, Phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2016.01.001_bib1055","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2016.01.001_bib0935","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0940","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib0945","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2016.01.001_bib0950","article-title":"Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study","author":"Baraliakos","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2016.01.001_bib0955","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a Phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2016.01.001_bib0960","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3899\/jrheum.130637","article-title":"One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: Phase II, dose-finding, double-blind, randomized, placebo-controlled study","volume":"41","author":"Genovese","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0965","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7525-12-31","article-title":"Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds","volume":"12","author":"Strand","year":"2014","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.molmed.2016.01.001_bib0970","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/kev258","article-title":"Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis","volume":"55","author":"Burmester","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.molmed.2016.01.001_bib0975","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.27334","article-title":"LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled, proof-of-concept study","volume":"62","author":"Genovese","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2016.01.001_bib0980","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"A Phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2016.01.001_bib0985","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3899\/jrheum.141271","article-title":"A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate","volume":"42","author":"Pavelka","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib0990","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar4347","article-title":"A Phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis","volume":"15","author":"Martin","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2016.01.001_bib0995","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2016.01.001_bib1000","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.ajpath.2013.02.029","article-title":"Anti-IL-17A treatment reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging in chronic relapsing EAE ABH mice","volume":"182","author":"Mardiguian","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2016.01.001_bib1005","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1517\/14712598.2014.887676","article-title":"Novel monoclonal antibodies for therapy of multiple sclerosis","volume":"14","author":"Knier","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.molmed.2016.01.001_bib1010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cytogfr.2014.07.013","article-title":"IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments","volume":"25","author":"Luchtman","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.molmed.2016.01.001_bib1015","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"Suppl. 2","key":"10.1016\/j.molmed.2016.01.001_bib1020","doi-asserted-by":"crossref","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","volume":"72","author":"Patel","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2016.01.001_bib1025","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/gutjnl-2012-302525","article-title":"Seventeen in Crohn's disease: less prime than we thought?","volume":"61","author":"Raine","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2016.01.001_bib1030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2016.01.001_bib1035","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.molmed.2016.01.001_bib1040","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/ICO.0000000000000627","article-title":"Dry eye signs and symptoms persist during systemic neutralization of IL-1\u03b2 by canakinumab or IL-17A by secukinumab","volume":"34","author":"Grosskreutz","year":"2015","journal-title":"Cornea"},{"key":"10.1016\/j.molmed.2016.01.001_bib1045","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaad.2015.08.057","article-title":"Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States","volume":"74","author":"Danesh","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molmed.2016.01.001_bib1050","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/annrheumdis-2014-207110","article-title":"A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis","volume":"74","author":"Ndongo-Thiam","year":"2015","journal-title":"Ann. Rheum. Dis."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491416000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491416000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T13:52:57Z","timestamp":1692193977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491416000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1471491416000125"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2016.01.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726192490.793533212","asserted-by":"object"}]},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-17 in Chronic Inflammation: From Discovery to Targeting","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2016.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}